Products
PRIMARY ANTIBODY
SECONDARY ANTIBODY
PROTEIN & PEPTIDES
BIOCHEMICALS
ASSAY & ELISA KITS
LOADING CONTROL
OTHER REAGENTS
SERUMS
CELL LINE
Contact Us
About Us
Login
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Products
Contact Us
About Us
Shopping Cart
Loading....
Login Account
Sign In
Register
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Home
BioChemicals
Zanubrutinib
tcsc0021869
Zanubrutinib
Order Now
AVAILABLE SIZES
1mg
5mg
10mg
50mg
$
271.00
Add to Cart
ORDERING INFORMATION
International
TAICLONE BIOTECH CORP.
order@taiclone.com
+886-2-2735-9682
+886-2-2735-9807
Data sheet
Download PDF Datasheet
Technical Inquries
Submit Review
Submit Review
Please choose your application, enter the information requested below. * Marked fields are mandatory.
Full Name
Email
Contact Number
Application
Please Select..
Western blot (WB)
Immunohistochemistry (IHC)
Immunofluorescence (IF)
Immunocytochemistry (ICC)
Immunoprecipitation (IP)
Co-Immunoprecipitation (CoIP)
Chromatin Immunoprecipitation (ChIP)
RNA Binding Protein Immunoprecipitation (RIP)
Sample
Loading Amount
Loading Type
UG
CELLS
Treatment
Temperature
Exposure
Observe Band
Fixative
Select One
Acetone
Formaldehyde
Methanol
Paraformaldehyde
Other
Antigen Retrieval
Select One
Heat mediated
Enzymatic
Other
None
Positive Control
Negative Control
Dilution *
1:
Incubation Time *
Select Image *
Choose a file...
Rating *
Remarks *
Submit Review
Product Description
Zanubrutinib is a selective
Bruton tyrosine kinase
(
BTK
) inhibitor.
IC50 & Target: BTK
[1]
In Vitro:
Zanubrutinib (BGB-3111) is a selective Bruton tyrosine kinase (BTK) inhibitor. In both biochemical and cellular assays, Zanubrutinib demonstrates nanomolar BTK inhibition activity. In several MCL and DLBCL cell lines, Zanubrutinib inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with ibrutinib, Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK
[1]
.
In Vivo:
Zanubrutinib (BGB-3111) induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts, Zanubrutinib at 2.5 mg/kg BID shows similar activity as ibrutinib at 50 mg/kg QD. In the systemic model, the median survival of Zanubrutinib 25 mg/kg BID group is significantly longer than those of both ibrutinib 50 mg/kg QD and BID groups. In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, Zanubrutinib also demonstrates better anti-tumor activity than ibrutinib. Preliminary 14-day toxicity study in rats shows that Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250 mg/kg/day
[1]
.
Information
CAS No
1691249-45-2
Formula
C
27
H
29
N
5
O
3
Clinical Information
clinicalinformation
Pathway
Protein Tyrosine Kinase/RTK
Target
Btk
Specifications
Purity / Grade
>98%
Solubility
DMSO : ≥ 56.75 mg/mL (120.35 mM); Ethanol : < 1 mg/mL (insoluble)
Smiles
smiles
Misc Information
Alternative Names
BGB-3111
Observed Molecular Weight
471.55
related data
Get valuable resources and offers directly to your email.
REGISTER NOW